02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring activated...
00:14 , Oct 28, 2017 |  BioCentury  |  Finance

Familiarity breeds opportunity

Confidence in Y-mAbs Therapeutics Inc.’s management team and late-stage programs in pediatric oncology where treatment options are sparse drove HBM Partners' decision to lead the company's $50 million venture round. Undisclosed existing investors also participated...
19:01 , Oct 27, 2017 |  BC Week In Review  |  Financial News

Y-mAb raises $50M round

Immunotherapy play Y-mAbs Therapeutics Inc. (New York, N.Y.) raised $50 million on Oct. 24 in a venture round led by new investor HBM Healthcare Investments. Existing investors also participated. Y-mAbs' lead candidates are naxitamab (Hu3F8), which...
21:30 , Oct 24, 2017 |  BC Extra  |  Financial News

Y-mAbs raises $50M round

Immunotherapy play Y-mAbs Therapeutics Inc. (New York, N.Y.) raised $50 million in a venture round led by new investor HBM Healthcare Investments. Existing investors also participated. Y-mAbs' lead candidates are naxitamab (Hu3F8), which is a humanized...
17:11 , Jun 15, 2017 |  BC Week In Review  |  Clinical News

Y-mabs gets FDA breakthrough therapy designation for neuroblastoma candidate burtomab

Y-mabs Therapeutics Inc. (New York, N.Y.) said FDA granted breakthrough therapy designation to burtomab (I-8H9) to treat pediatric patients with relapsed or refractory neuroblastoma with CNS or leptomeningeal metastasis. The company has reported data from a...